2020 Guide to Patient Support Services

Janssen Biotech

Janssen Biotech, through Janssen CarePath, offers 1 source for patient support services, focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication.

The Janssen CarePath program also includes patient information about each medication offered, as well as other patient support services. Other tools are available to help patients stay on track with taking and keeping up with their medication regimens.

The complete list of Janssen Biotech’s oncology and supportive care medications is provided in the Table.

JANSSEN CAREPATH SAVINGS PROGRAM

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to Janssen oncology medications.

The Janssen CarePath Savings Program may provide patients with a rebate for their out-of-pocket prescription costs. This program is geared toward patients who have commercial or private health insurance.

Balversa Janssen CarePath Savings Program

Patients who have been prescribed Balversa (erdafitinib) and have private insurance may be able to save on their copay, coinsurance, and deductible medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay just $5 per month for Balversa, with an annual benefit up to $25,000. This program is not available for patients who have Medicare, Medicaid, or other government-funded healthcare programs used to pay for their medications.

Darzalex Janssen CarePath Savings Program

Patients who have been prescribed Darzalex (daratumumab) may be able to save on their copay, deductible, and coinsurance medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Darzalex, up to a $20,000 annual benefit.

Erleada Janssen CarePath Savings Program

Eligible patients who have private insurance may pay only $0 per month for Erleada (apalutamide), with an annual benefit up to $15,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Yondelis Janssen CarePath Savings Program

Patients who have been prescribed Yondelis (trabectedin) may be able to save on their copay, deductible, and coinsurance medication costs through the Janssen CarePath Savings Program. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Yondelis, with a maximum benefit of $20,000 annually.

Zytiga Janssen CarePath Savings Program

Patients who have been prescribed Zytiga (abiraterone acetate) may be able to save on their copay, deductible, and coinsurance costs through the Janssen CarePath Savings Program.

Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay $10 monthly for Zytiga, up to a $12,000 annual benefit, 12 months after the card activation or after 12 doses, whichever comes first.

Johnson & Johnson Patient Assistance Foundation

The Johnson & Johnson Patient Assistance Foundation is an independent, nonprofit organization that helps patients without adequate financial resources and with no prescription coverage obtain their medications. The program is drug-specific, and qualifying patients may be eligible to receive free Janssen medications for up to 12 months.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the foundation’s patient assistance program, is available at JJPAF.org.

ELIGIBILITY

Janssen CarePath Savings Program

Patients may qualify for enrollment in the Janssen CarePath Savings Program if they currently have private or commercial health insurance that will cover a portion of the cost of medication, including Balversa, Darzalex, Erleada, or Yondelis. Patients participating in federal- or state-funded programs are not eligible for the savings program. Those patients are directed to programs that can help them to afford their medications. Drug-specific eligibility criteria are available at JanssenCarePath.com.

Johnson & Johnson Patient Assistance Foundation

To qualify for enrollment in the Johnson & Johnson Patient Assistance Foundation, patients must:

  • Reside in the United States or its territories
  • Receive outpatient treatment from a licensed US provider
  • Lack prescription drug coverage
  • Meet drug-specific income eligibility requirements, available at JJPAF.org/eligibility.

Janssen CarePath Savings Program Cards

Patients who are prescribed Janssen Biotech medications may qualify for a drug-specific Janssen CarePath Savings Program Card if they meet the following criteria:

  • They have been prescribed Balversa, Darzalex, Erleada, Yondelis, or Zytiga
  • They have eligible private insurance
  • They are not enrolled in a federal- or a state-subsidized healthcare plan or program.

APPLICATION & ENROLLMENT

Janssen CarePath Savings Program

The enrollment process for this program varies by medication. To learn more about the application process for a specific drug, visit JanssenCarePath.com and select the prescribed medication from the drop-down menu.

Johnson & Johnson Patient Assistance Foundation

To enroll in the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form.

Applications, and any required documentation, may be faxed to 888-526-5168, or mailed to the address listed on the form. The patient’s medical information, including the diagnosis (and a diagnosis code) and medication-specific information (with the dosage), must be completed.

For Procrit (epoetin alfa), the hemoglobin level based on the most recent laboratory results must be included.

REIMBURSEMENT

Information about reimbursement support programs for eligible patients is accessible through the CarePath portal. Reimbursement programs are drug-specific. The reimbursement programs pertaining to Janssen’s oncology and oncology supportive care drugs are drug-specific.

Darzalex
Information about Darzalex reimbursement programs can be found online or by phone at 844-553-2792.

Erleada
Janssen CarePath offers Erleada-specific reimbursement support, resources, and tools for patients and providers. Click here for more information or call 833-375-3232.

Procrit
Procrit-specific reimbursement support, resources, and tools for patients and providers are available online or over the phone by dialing 800-553-3851.

Yondelis
For patients who are prescribed infusions of Yondelis, click here for more information, or call 844-966-3354.

Zytiga
Patients who have been prescribed Zytiga may be able to save on copays, deductibles, and coinsurance. Enrollment forms are available online.

TABLE JANSSEN BIOTECH ONCOLOGY/SUPPORTIVE CARE DRUGS

Drugs
Indications
Patient support programs

Drug
Balversa (erdafitinib) tablets
Indications
Treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alternation, as determined by an FDA-approved test, that has progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Patient support programs

Drug
Darzalex (daratumumab)
Indications
Patient support programs

Drug
Erleada (apalutamide)
Indications
Nonmetastatic castration-resistant prostate cancer
Patient support programs

Drug
Procrit (epoetin alfa)
Indications
Chemotherapy-induced anemia
Patient support programs

Drug
Yondelis (trabectedin)
Indications
Unresectable or metastatic liposarcoma or leiomyosarcoma
Patient support programs

Drug
Zytiga (abiraterone acetate)
Indications
Metastatic castration-resistant prostate cancer, in combination with prednisone; metastatic high-risk, castration-sensitive prostate cancer, in combination with prednisone
Patient support programs

Darzalex (daratumumab) Indications

Treatment of newly diagnosed multiple myeloma in patients ineligible for autologous stem-cell transplant (ASCT), or treatment of relapsed or refractory multiple myeloma after ≥1 previous therapies, in combination with lenalidomide and dexamethasone; first-line treatment of multiple myeloma in patients eligible for ASCT, in combination with combination with bortezomib, melphalan, and prednisone; multiple myeloma, in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, after ≥1 previous therapies; multiple myeloma, in combination with pomalidomide and dexamethasone after ≥2 previous therapies, including lenalidomide and a proteasome inhibitor; multiple myeloma, as monotherapy, after ≥3 previous lines of therapy

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: